Madrigal Pharmaceuticals, Inc.
MDGL
$425.85
-$9.77-2.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 958.40M | 740.64M | 515.55M | 317.38M | 180.13M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 958.40M | 740.64M | 515.55M | 317.38M | 180.13M |
| Cost of Revenue | 56.15M | 35.15M | 19.18M | 10.75M | 6.23M |
| Gross Profit | 902.26M | 705.50M | 496.37M | 306.64M | 173.90M |
| SG&A Expenses | 813.83M | 715.07M | 613.54M | 522.13M | 435.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.26B | 1.05B | 825.36M | 742.53M | 678.01M |
| Operating Income | -300.10M | -307.48M | -309.81M | -425.15M | -497.87M |
| Income Before Tax | -288.28M | -289.13M | -281.90M | -391.59M | -465.89M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -288.28 | -289.13 | -281.90 | -391.59 | -465.89 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -288.28M | -289.13M | -281.90M | -391.59M | -465.89M |
| EBIT | -300.10M | -307.48M | -309.81M | -425.15M | -497.87M |
| EBITDA | -298.59M | -306.01M | -308.40M | -423.84M | -496.78M |
| EPS Basic | -12.86 | -13.01 | -12.85 | -18.04 | -22.11 |
| Normalized Basic EPS | -7.96 | -8.05 | -8.03 | -11.28 | -13.82 |
| EPS Diluted | -12.86 | -13.01 | -12.85 | -18.04 | -22.11 |
| Normalized Diluted EPS | -7.96 | -8.05 | -8.03 | -11.28 | -13.82 |
| Average Basic Shares Outstanding | 89.61M | 88.71M | 87.97M | 87.17M | 85.08M |
| Average Diluted Shares Outstanding | 89.61M | 88.71M | 87.97M | 87.17M | 85.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |